ClinicalTrials.gov
ClinicalTrials.gov Menu

Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00653354
Recruitment Status : Completed
First Posted : April 4, 2008
Last Update Posted : April 10, 2008
Sponsor:
Information provided by:
Pfizer

Study Description
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To assess the analgesic efficacy and general safety of 2 dosing regimens of valdecoxib compared to placebo on the first post-operative day in patients with moderate or severe pain following bunionectomy surgery.

Condition or disease Intervention/treatment Phase
Pain, Post-Surgical Drug: valdecoxib Drug: valdecoxib/placebo Drug: placebo Phase 3

Study Design
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Assessment Of The Analgesic Efficacy Of The Dosing Regimen Of Valdecoxib Compared To Placebo Patients In Pain Following Bunionectomy
Study Start Date : December 2002
Actual Study Completion Date : March 2003

Resource links provided by the National Library of Medicine

Drug Information available for: Valdecoxib
U.S. FDA Resources

Arms and Interventions
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Arm 1 Drug: valdecoxib
valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
Active Comparator: Arm 2 Drug: valdecoxib/placebo
valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
Placebo Comparator: Arm 3 Drug: placebo
placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose


Outcome Measures
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Summed Pain Intensity Difference (categorical) through 24 hours (SPID 24) [ Time Frame: Day 1 ]
  2. Total Pain Relief through 24 hours (TOTPAR 24) [ Time Frame: Day 1 ]
  3. Patient's Global Evaluation of Study Medication [ Time Frame: Day 1 ]

Secondary Outcome Measures :
  1. time between doses of study medication [ Time Frame: Day 1 ]
  2. Time-specific Pain Intensity Difference (PID) (categorical) [ Time Frame: 0, 2, 4, 6, 8, 10, 12, 16, and 24 hours ]
  3. time-specific pain relief [ Time Frame: 2, 4, 6, 8, 10, 12, 16, and 24 hours ]
  4. time-specific PID (VAS) [ Time Frame: 0, 2, 4, 6, 8, 10, 12, 16, and 24 hours ]
  5. Summed Pain Intensity (SPID)24 (VAS) [ Time Frame: 0, 2, 4, 6, 8, 10, 12, 16, and 24 hours ]
  6. time to rescue medication [ Time Frame: 2, 4, 6, 8, 10, 12, 16, and 24 hours ]
  7. percent of patients who took rescue medication [ Time Frame: Day 1 ]
  8. Patient's Satisfaction Questionnaire [ Time Frame: Day 1 ]

Eligibility Criteria
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who underwent an uncomplicated primary unilateral first metatarsal bunionectomy surgery (with or without ipsilateral hammer toe repair) requiring open manipulation of bone with periosteal elevation under regional anesthesia (Mayo block)
  • Patients had a Baseline pain intensity of moderate or severe on a categorical scale and ≥45 mm on a VAS

Exclusion Criteria:

  • Patients who were scheduled to undergo other surgical procedures that would be expected to produce a greater degree of surgical trauma than the orthopedic procedure alone
  • Patients treated with patient controlled analgesia (PCA) subsequent to the end of anesthesia
  • Patients treated with long-acting local anesthetics or local anesthetics coadministered with epinephrine injected into the index joint space
  • Patients expected to require analgesics or other agents other than study medication during the 8 hours preceding administration of study medication through the end of the treatment period, that could confound assessment of the analgesic response, specifically excluded were tricyclic antidepressants, tranquilizers, neuroleptics, neuroleptic antiemetics, cyclooxygenase-2 inhibitors, nonsteroidal antiinflammatory drugs, and corticosteroids
Contacts and Locations
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00653354


Locations
United States, Arizona
Pfizer Investigational Site
Phoenix, Arizona, United States, 85015
Pfizer Investigational Site
Phoenix, Arizona, United States, 85016
Pfizer Investigational Site
Phoenix, Arizona, United States, 85020
Pfizer Investigational Site
Phoenix, Arizona, United States, 85032
Pfizer Investigational Site
Tempe, Arizona, United States, 85281
United States, California
Pfizer Investigational Site
Anaheim, California, United States, 92701
Pfizer Investigational Site
Chula Vista, California, United States, 91911
Pfizer Investigational Site
San Diego, California, United States, 92114
Pfizer Investigational Site
Santa Ana, California, United States, 92701
Pfizer Investigational Site
Tustin, California, United States, 92780
United States, Kentucky
Pfizer Investigational Site
Lexington, Kentucky, United States, 40504
Pfizer Investigational Site
Lexington, Kentucky, United States, 40509
Pfizer Investigational Site
Lexington, Kentucky, United States, 40515
United States, Pennsylvania
Pfizer Investigational Site
Altoona, Pennsylvania, United States, 16602
Pfizer Investigational Site
Duncansville, Pennsylvania, United States, 16635
United States, Tennessee
Pfizer Investigational Site
Johnson City,, Tennessee, United States, 37601
Pfizer Investigational Site
Johnson City, Tennessee, United States, 37601
Pfizer Investigational Site
Johnson City, Tennessee, United States, 37604
United States, Texas
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
Pfizer Investigational Site
San Antonio, Texas, United States, 78240
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84117
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84123
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
More Information
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00653354     History of Changes
Other Study ID Numbers: VALA-0513-149
A3471086
First Posted: April 4, 2008    Key Record Dates
Last Update Posted: April 10, 2008
Last Verified: April 2008

Keywords provided by Pfizer:
hallux valgus

Additional relevant MeSH terms:
Analgesics
Valdecoxib
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
 Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents